Blueprint

News

Blueprint gets first approval as FDA backs stomach cancer dr...

US biotech Blueprint Medicines has its first approved drug, after the FDA backed its oncology drug Ayvakit for a certain kind of stomach cancer.

News

Blueprint eyes quick filing for GIST drug avapritinib

Blueprint Medicines has new data for its lead cancer drug avapritinib in gastrointestinal stromal tumours (GIST) that set it on course for regulatory filings – and a close race to market wi

News

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks